FMC Corp's Earnings and Revenues Surpass Estimates in Q1

01.05.25 13:28 Uhr

Werte in diesem Artikel
Aktien

34,08 EUR -2,40 EUR -6,58%

44,58 EUR 0,81 EUR 1,85%

Indizes

PKT PKT

1.979,6 PKT 47,2 PKT 2,44%

2.045,9 PKT 51,4 PKT 2,58%

23.086,7 PKT 589,7 PKT 2,62%

8.791,3 PKT 206,4 PKT 2,40%

1.820,8 PKT 43,3 PKT 2,43%

2.975,3 PKT 0,8 PKT 0,03%

2.143,9 PKT 0,6 PKT 0,03%

201,6 PKT 0,8 PKT 0,41%

552,9 PKT 11,4 PKT 2,11%

12.053,0 PKT 293,0 PKT 2,49%

23.120,0 PKT -4,0 PKT -0,02%

23.092,4 PKT 509,4 PKT 2,26%

8.920,7 PKT 223,1 PKT 2,56%

17.575,1 PKT 286,6 PKT 1,66%

1.854,4 PKT -8,4 PKT -0,45%

FMC Corporation FMC reported a loss of 12 cents per share for first-quarter 2025. This compares unfavorably to loss of 2 cents incurred in the year-ago quarter.Barring one-time items, adjusted earnings per share were 18 cents, beating the Zacks Consensus Estimate of 8 cents.Revenues were $791.4 million in the quarter, down around 13.8% from the year-ago quarter’s levels. The top line beat the Zacks Consensus Estimate of $779 million.The top line fell due to a price decline of 9%, more than half of which was related to price adjustments in certain contracts with specific diamide partners.(Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)FMC Corporation Price, Consensus and EPS Surprise FMC Corporation price-consensus-eps-surprise-chart | FMC Corporation QuoteFMC’s Regional Sales PerformanceIn North America, sales tumbled 28% year over year to $186 million in the quarter on reduced volumes. The figure missed the consensus estimate of $224.2 million. The decline was primarily due to lower volumes as customers in the United States delayed purchases as anticipated, which was exacerbated by international trade dynamics.Latin American sales saw a 10% year-over-year rise to $207 million in the reported quarter. It beat the consensus estimate of $137.9 million. Volume grew due to increasing direct sales to cotton growers in Brazil, as well as product-on-the-ground sales surpassing FMC sales into the channel. In Asia, revenues declined 24% from the prior-year quarter to $125 million. It lagged the consensus estimate of $144.8 million. Prudent selling to allow channel destocking led to lower volumes.EMEA sales fell 11% year over year to $273 million in the reported quarter. It missed the consensus estimate of $278.5 million. EMEA sales are being adversely impacted by lower volumes, including the expected loss of registration for triflusulfuron.FMC’s FinancialsThe company had cash and cash equivalents of $315.3 million at the end of the quarter, down roughly 11.8% sequentially. Long-term debt was $3,027.7 million, flat sequentially.FMC’s GuidanceThe company has maintained its revenue outlook for the year at $4.15 billion to $4.35 billion, which is essentially flat compared to the prior year at the midpoint. The adjusted EBITDA forecast also remains unchanged at $870 million to $950 million, implying a 1% increase at the midpoint from the prior year, or a 4% increase when excluding the GSS divestiture impact. This guidance includes estimated incremental tariff costs of $15 million to $20 million, based on the latest government guidelines. The company has also reiterated its adjusted earnings per diluted share outlook of $3.26 to $3.70, which is flat at the midpoint compared to the previous year. Additionally, the free cash flow forecast remains at $200 million to $400 million.FMC’s Price PerformanceFMC’s shares have lost 30.8% in the past year compared with a 9.6% decline of the industry.Image Source: Zacks Investment ResearchFMC’s Zacks Rank & Key PicksFMC currently carries a Zacks Rank #3 (Hold).Better-ranked stocks worth a look in the basic materials space include Hawkins, Inc. HWKN, SSR Mining Inc. SSRM and Intrepid Potash, Inc. IPI. While HWKN carries a Zacks Rank #1 (Strong Buy), SSRM and IPI carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.Hawkins is expected to report fiscal fourth-quarter results on May 21. The consensus estimate for Hawkins’ earnings is pegged at 74 cents. HWKN beat the consensus estimate in one of the last four quarters while missing thrice, with the average earnings surprise being 6.1%. SSRM is scheduled to release first-quarter results on May 6. The Zacks Consensus Estimate for SSRM’s first-quarter earnings is pegged at 8 cents. SSRM has a trailing four-quarter earnings surprise of 155.7%, on average.  Intrepid Potash is slated to release first-quarter results on May 5. The consensus estimate for IPI’s first-quarter loss is 12 cents, stable over the past 60 days. Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report FMC Corporation (FMC): Free Stock Analysis Report Intrepid Potash, Inc (IPI): Free Stock Analysis Report Silver Standard Resources Inc. (SSRM): Free Stock Analysis Report Hawkins, Inc. (HWKN): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: FMC und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.

Ausgewählte Hebelprodukte auf FMC

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf FMC

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Fresenius Medical Care (FMC) St.

Wer­bung

Analysen zu Fresenius Medical Care (FMC) St.

DatumRatingAnalyst
23.04.2025Fresenius Medical Care (FMC) St NeutralUBS AG
23.04.2025Fresenius Medical Care (FMC) St BuyGoldman Sachs Group Inc.
22.04.2025Fresenius Medical Care (FMC) St HoldDeutsche Bank AG
22.04.2025Fresenius Medical Care (FMC) St BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
22.04.2025Fresenius Medical Care (FMC) St Equal WeightBarclays Capital
DatumRatingAnalyst
23.04.2025Fresenius Medical Care (FMC) St BuyGoldman Sachs Group Inc.
22.04.2025Fresenius Medical Care (FMC) St BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
12.03.2025Fresenius Medical Care (FMC) St BuyGoldman Sachs Group Inc.
27.02.2025Fresenius Medical Care (FMC) St KaufenDZ BANK
25.02.2025Fresenius Medical Care (FMC) St BuyGoldman Sachs Group Inc.
DatumRatingAnalyst
23.04.2025Fresenius Medical Care (FMC) St NeutralUBS AG
22.04.2025Fresenius Medical Care (FMC) St HoldDeutsche Bank AG
22.04.2025Fresenius Medical Care (FMC) St Equal WeightBarclays Capital
16.04.2025Fresenius Medical Care (FMC) St Market-PerformBernstein Research
04.03.2025Fresenius Medical Care (FMC) St Market-PerformBernstein Research
DatumRatingAnalyst
17.04.2025Fresenius Medical Care (FMC) St UnderweightJP Morgan Chase & Co.
21.03.2025Fresenius Medical Care (FMC) St UnderperformJefferies & Company Inc.
04.03.2025Fresenius Medical Care (FMC) St UnderperformJefferies & Company Inc.
26.02.2025Fresenius Medical Care (FMC) St UnderweightJP Morgan Chase & Co.
25.02.2025Fresenius Medical Care (FMC) St UnderperformJefferies & Company Inc.

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Fresenius Medical Care (FMC) St. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen